Li's Pharmaceutical Co., Ltd. announced that the new drug clinical trial application submitted by the company in China for the proprietary ADC project ZK2401 was accepted by the Drug Evaluation Center of the China National Drug Administration on July 29, 2026. ZK2401 is an ADC project based on the company's self-developed anti-PD-L1 antibody socazolimab and coupled with a novel topoisomerase I inhibitor load. It is the first project on the company's ADC platform. The review period is expected to be about 30 working days, and clinical trial approval is expected as early as September 2026.

Li's Pharmaceutical Co., Ltd. announced that the new drug clinical trial application submitted by the company in China for the proprietary ADC project ZK2401 was accepted by the Drug Evaluation Center of the China National Drug Administration on July 29, 2026. ZK2401 is an ADC project based on the company's self-developed anti-PD-L1 antibody socazolimab and coupled with a novel topoisomerase I inhibitor load. It is the first project on the company's ADC platform. The review period is expected to be about 30 working days, and clinical trial approval is expected as early as September 2026.